Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenotypes, genotypes and response to statin therapy.

Muriel J Caslake1, Chris J Packard

  • 1Department of Vascular Biochemistry, Glasgow Royal Infirmary, Glasgow, Scotland, UK. m.caslake@clin-med.gla.ac.uk

Current Opinion in Lipidology
|July 10, 2004
PubMed
Summary

Statin effectiveness varies due to genetics and obesity. Understanding these factors, especially plasma triglyceride levels, helps tailor statin therapy for better lipid lowering and personalized treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same author

Clinical relevance of per-particle atherogenicity of triglyceride-rich lipoproteins, Lp(a) and LDL for cardiovascular risk.

Pharmacology & therapeutics·2026
Same author

Apolipoprotein C-III: Risk-factor, Regulator of Triglyceride-rich Lipoprotein Metabolism and Therapeutic Target.

Current atherosclerosis reports·2026
Same author

Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.

European heart journal·2026
Same author

Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know.

Atherosclerosis·2025
Same author

Editorial: The Brussels International Declaration on Lp(a) Testing And Management-A call to action.

Atherosclerosis·2025

Area of Science:

  • Pharmacogenomics
  • Lipid Metabolism
  • Cardiovascular Therapeutics

Background:

  • Statin therapy response varies significantly among individuals.
  • Genetic (genotype) and acquired (phenotype) factors influence statin efficacy.
  • Obesity and plasma triglyceride levels are key phenotypic determinants.

Purpose of the Study:

  • To review factors influencing patient response to statin treatment.
  • To elucidate the mechanism of plasma triglyceride's influence on statin-induced lipid lowering.
  • To explore genotype-phenotype interactions in statin therapy.

Main Methods:

  • Literature review of studies on statin response.
  • Analysis of lipid profiles in relation to triglyceride levels and statin use.

Related Experiment Videos

  • Examination of genetic polymorphisms (e.g., ABCG8, apolipoprotein A1) and their impact on statin outcomes.

    • Main Results:

    • Statins show phenotype-dependent effects on VLDL, chylomicrons, and LDL, particularly in hypertriglyceridemic individuals.
    • Lipoprotein clearance stimulation is the primary mechanism for statin-induced VLDL/LDL reduction in hypertriglyceridemia.
    • Genetic variations (ABCG8 D19H, apolipoprotein A1 promoter) correlate with differential LDL-cholesterol and HDL-cholesterol responses.
    • Statin use in low HDL-cholesterol individuals increases alpha1 HDL components.

    Conclusions:

    • Statin therapy is currently empirical, highlighting the need for personalized approaches.
    • Considering phenotype and genotype will enable more tailored and effective statin prescriptions.
    • Further research into genetic and metabolic influences can optimize cardiovascular disease management.